The Medtechy Daily: November 19, 2018
Posted on November 19, 2018 by Medtech[y] Staff
The Medtechy Daily provides the latest news and insight for the medical technology industry, including medical device, biotech and digital health.
Tweet of the Day
The US medical-industrial complex includes 4 industries: hospitals, doctors, drug & device makers, & insurers. They make US healthcare more costly than in any other country.— Richard D. Wolff (@profwolff) November 17, 2018
When they call all criticism and better alternatives “socialism,” its about their profits, nothing else.
Verily and Alcon pull the plug on glucose-sensing contact lens. Verily's Chief Technology Officer, Brian Otis, shared on Verily's blog that the company and Alcon have decided to put the glucose-sensing contact lens project on hold. (Medtechy)
Pfizer, plotting 41 price hikes for January, returns to 'business as normal' after price-raising pause. Pfizer, which became the center of a drug pricing controversy this summer featuring President Donald Trump, has decided it’s ready to raise prices in early 2019. (FiercePharma)
How to Work for a Boss Who Has a New Idea Every 5 Minutes. Visionary bosses can be exciting, fun, and innovative. They can also feel overwhelming when there’s no way that you can keep up with all of their creative ideas. (Harvard Business Review)
Abbott Nabs Approvals for DRG Invisible Trial System. Abbott Laboratories has nabbed approvals for a chronic pain treatment device that patients can try before getting an implanted version of the technology. The Dorsal Root Ganglion (DRG) Invisible Trial System now has CE mark and a nod from FDA. (MDDI)
Edwards' Sapien 3 Ultra Valve Wins CE Mark. As expected, Edwards Lifesciences has secured a CE mark for its Sapien 3 Ultra device, but the company won't be able to release the new transcatheter aortic valve replacement (TAVR) system in Germany due to a recent preliminary injunction from Boston Scientific. (MDDI)
OTC drugmakers face an uphill battle on Amazon. But they should still be there, expert says. Amazon is now the third-largest digital ad platform, but pharma marketers are mostly shut out. That’s because most of Amazon’s ads are for products sold by retailers, and of course, prescription drugs can't be purchased that way. (FiercePharma)